Perspective Therapeutics, Inc.

EX-99.1 · catx-ex99_1.htm

EX-99.1
 2
 catx-ex99_1.htm
 EX-99.1

 Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

  

 Engineering the Alpha Advantage in Targeted Oncology

 Unlocking New Treatment Options Across Solid Tumors:

 Optimizing the Entire System

 Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

 Optimizing Structural Chemistry:

 Choosing The Right Isotope

 Not All ²¹²Pb Programs Are Created Equal

  

 Advancing a Theranostic Approach:

 Solid Tumors are an Attractive Market for Radiopharmaceuticals

 Expanding the Addressable Market

 Direct-to-Hospital Delivery through Integrated Isotope Production

 Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product

 Reaching the Largest Addressable Market with Regional Manufacturing

 Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

 SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

 VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

 Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs

 VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis

 Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis

 VMT-α-NET Responses Deepen Over Time

 VMT-⍺-NET: Durable Disease Control Across All Doses

 Spider Plot of Tumor Change Over Time by Patient

 Best-in-class Safety Profile1

 Blood Creatinine During Follow-up for All Patients Treated (n=68)

 VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level

 Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

 VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

 Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

 Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01

 Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 10% of Patients)

 VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development

 FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

 PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

 Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

 PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

 Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

  

 A Decade of Deliberate, End-to-End Engineering

 Built Over a Decade:

  

 Abbreviations

 APPENDIX

  

 NETs Trials

 Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

 Refractory Metastatic Melanoma Trials

 ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma

  

  

 Construct designed for better clinical outcome

 212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors